Timing of Dose Relative to Sexual Intercourse Attempt in Previous Sildenafil Citrate Users Treated with Tadalafil

Glina, Sidney; Sotomayor, Mariano; Gatchalian, Eduardo R.; Yaman, Önder; D’yachkova, Yulia; Markey, Caroline M.; Kopernicky, Vladimir

doi:10.1111/j.1743-6109.2006.00220.x

Cited by 9 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eighty-two percent of the patients who changed treatment from another PDE5 inhibitor reported remaining on tadalafil after 1 year, with improvement in ED severity. This observation is consistent with a similar response to tadalafil observed in naïve patients and sildenafil prior responders [35], and a change in timing of sexual intercourse relative to dose in previous sildenafil users treated with tadalafil [22] that may translate in preference for tadalafil vs. sildenafil as shown in a crossover study [24,36] as well as switch study [37].…”

Section: Discussionsupporting

confidence: 84%

“…At baseline, responses to the International Index of Erectile Dysfunction-erectile function (IIEF-EF) domain were collected [26], together with information on previous treatments for ED and reasons for discontinuation, demographics, concomitant diseases, duration and etiology of ED, relationship history, and expectations of treatment. The IIEF-EF domain score was used to categorize the severity of ED: severe (score 1-10), moderate (score [11][12][13][14][15][16], mild (score [17][18][19][20][21][22][23][24][25], and normal (score Ն 26).…”

Section: Methodsmentioning

confidence: 99%

“…Tadalafil is unique among the commercially approved PDE5 inhibitors because it has a long period of responsiveness that lasts up to 36 hours after dosing and can be taken with or without food [11,[19][20][21][22][23]. These characteristics of tadalafil may facilitate its correct use in a real-life setting and could increase patient response and satisfaction [24,25].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic Response after First Month of Tadalafil Treatment Predicts 12 Months Treatment Continuation in Patients with Erectile Dysfunction: Results from the DETECT Study

Roumeguère

Verheyden

Arver

et al. 2008

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction The DETECT study is a prospective, 12-month, European, multicenter, observational study of patients with erectile dysfunction (ED) initiating or changing treatment to tadalafil in routine clinical practice. Aim To determine the effectiveness of tadalafil and the factors associated with the continuation of treatment for ED at 12 months. Methods The DETECT study included 1,900 men aged 18 years and older with a history of ED and who were initiating or changing treatment to tadalafil. Main Outcome Measures Sexual function at baseline, 1, 6, and 12 months was assessed using the International Index of Erectile Function-erectile function (IIEF-EF) domain. Factors associated with treatment continuation at 12 months were evaluated using multivariate regression analysis. Results At 12 months, 1,319 (84%) of 1,567 patients who completed the questionnaire reported continued use of tadalafil. Among these patients, tadalafil was highly effective: 94%, 95%, and 71% with severe, moderate, and mild ED at baseline, respectively, improved by at least one IIEF-EF category and 65% had normal EF. Five factors were associated with tadalafil continuation at 12 months: (i) ED severity at 1 month (based on IIEF-EF domain score); (ii) tolerance to treatment at 1 month; (iii) age younger than 60 years; (iv) number of sexual attempts in the first month; and (v) no history of pelvic surgery. Patient and partner factors at baseline were not significantly associated with continued tadalafil use. Conclusions Tadalafil is an effective treatment for ED in routine clinical practice. The therapeutic response and treatment tolerance after 1-month treatment are the most important factors influencing tadalafil continuation.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Response after First Month of Tadalafil Treatment Predicts 12 Months Treatment Continuation in Patients with Erectile Dysfunction: Results from the DETECT Study

Roumeguère

Verheyden

Arver

et al. 2008

The Journal of Sexual Medicine

View full text Add to dashboard Cite

show abstract

“…Similarly, patients taking tadalafil attempted intercourse up to 36 h after tadalafil dosing when instructed that they could do so (79)(80)(81)108). Data from the recent, 12-month DETErminants of Continued use of Tadalafil (DETECT) study suggested that early success with tadalafil was a determinant of long-term outcomes, including medication adherence (Figure 4; 109).…”

Section: Pharmacokineticsmentioning

confidence: 99%

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction

Sadovsky

Brock

Gutkin³

et al. 2009

International Journal of Clinical Practice

View full text Add to dashboard Cite

Despite the marked adverse impacts of erectile dysfunction (ED) on quality of life and well-being, many patients (and/or their partners) do not seek medical attention for this problem, do not receive treatment or discontinue such treatment even when it has effectively restored erectile responses to sexual stimulation. Phosphodiesterase type 5 (PDE5) inhibitors are considered first-line therapies for men with ED. To help physicians maximise the likelihood of treatment success with these agents, we conducted an English-language PubMed search of articles involving approved PDE5 inhibitors dating from 1 January 1998 (the year in which sildenafil citrate was introduced), through 31 August 2008. In addition to sildenafil, tadalafil and vardenafil, search terms included ‘adhere*’, ‘couple*’, ‘effect*’, ‘effic*’, ‘partner*’, ‘satisf*’, ‘succe*’ and ‘treatment outcome.’ Based on our analysis, physician activities to promote favourable treatment outcomes may be captured under the mnemonic ‘EPOCH’: (i) Evaluating and educating patients and partners to ensure realistic expectations of therapy; (ii) Prescribing a treatment individualised to the couple’s lifestyle needs and other preferences; (iii) Optimising treatment outcomes by scheduling follow-up visits with the patient to ‘fine-tune’ dosages and revisit key educational messages; (iv) Controlling comorbidities via lifestyle counselling, medications and/or referrals and (v) Helping patients and their partners to meet their health and psychosocial needs, potentially referring them to a specialist for other forms of therapy if they are not satisfied with PDE5 inhibitors.

show abstract

“…The present study was conducted to examine to what extent prior sildenafil citrate users modify their sexual intercourse and drug intake timing behavior when exposed to tadalafil with respective dosing instructions. Results for the overall study population, which included 2,760 patients from 21 countries, have been published previously [5]. This report reexamines those data by geographical region.…”

Section: Introductionmentioning

confidence: 53%

Timing of Dose Relative to Sexual Intercourse Attempt in Previous Sildenafil Citrate Users Treated with Tadalafil: A Geographical Comparison from a Single Arm, Open-Label Study

Rubio‐Aurioles¹,

Glina²,

Abdo

et al. 2009

The Journal of Sexual Medicine

Self Cite

View full text Add to dashboard Cite

Introduction Previous research has demonstrated that sildenafil citrate users alter dosing-sexual attempt behavior when switched to tadalafil. The impact of geography and culture on sexual behavior with phosphodiesterase type 5 (PDE5) inhibitor treatment has not been fully investigated. Aim To describe and compare the changes in dosing-sexual attempt behavior with sildenafil citrate vs. tadalafil treatment across four distinct geographies: Asia, Australia/New Zealand (ANZ), Central Eastern Europe/Middle East (CEE/ME), and Latin America (LA). Methods Data from a single-arm, open-label clinical trial conducted in 21 countries from November 2002 to May 2004 were used in this analysis. Men with erectile dysfunction and a history of ≥6-week prior sildenafil citrate use continued sildenafil citrate treatment for 4 weeks then switched to tadalafil for 8 weeks. Dosing instructions were provided. Main Outcomes Measures Timing of dose and sexual intercourse was assessed through patient diaries for the final 4 weeks of each treatment period. Results A total of 2,760 men were enrolled: Asia 15.8%; ANZ 29.4%; CEE/ME 19.7%; LA 35.1%. The median time from dosing to intercourse was significantly increased during tadalafil treatment across all geographical regions; however, the magnitude of increase differed significantly by geography (P < 0.0001). The Asian cohort demonstrated the shortest duration between dosing and sexual intercourse attempts (irrespective of drug), and altered sexual behavior the least upon switching to tadalafil. The ANZ cohort demonstrated the longest duration between dosing and sexual intercourse attempts (irrespective of drug), and altered sexual behavior the most upon switching to tadalafil. Conclusion Men with a history of established sildenafil citrate use alter their dose-attempt behavior when treated with tadalafil irrespective of geography. However, the extent to which sexual behavior alters is not uniform across geographical regions, suggesting that dosing instructions and duration of drug effectiveness, in combination with personal and cultural preferences, may determine sexual behavior with PDE5 inhibitor use.

show abstract

Timing of Dose Relative to Sexual Intercourse Attempt in Previous Sildenafil Citrate Users Treated with Tadalafil

Cited by 9 publications

References 8 publications

Therapeutic Response after First Month of Tadalafil Treatment Predicts 12 Months Treatment Continuation in Patients with Erectile Dysfunction: Results from the DETECT Study

Therapeutic Response after First Month of Tadalafil Treatment Predicts 12 Months Treatment Continuation in Patients with Erectile Dysfunction: Results from the DETECT Study

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction

Timing of Dose Relative to Sexual Intercourse Attempt in Previous Sildenafil Citrate Users Treated with Tadalafil: A Geographical Comparison from a Single Arm, Open-Label Study

Contact Info

Product

Resources

About